Declining CA-125 in an Ovarian Cancer Patient with Progression of Measurable Disease: A Rational Hypothesis for Discordant Results
- 1 May 2000
- journal article
- case report
- Published by Elsevier in Gynecologic Oncology
- Vol. 77 (2) , 321-322
- https://doi.org/10.1006/gyno.2000.5787
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or PaclitaxelJournal of Clinical Oncology, 1999
- CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?Cancer, 1996
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Modulation of 5-Fluorouracil with High-Dose Leucovorin Calcium: Activity in Ovarian Cancer and Correlation with CA-125 LevelsGynecologic Oncology, 1995
- A Proposal to Use CA-125 to Evaluate Activity of New Antineoplastic Agents in Ovarian CancerGynecologic Oncology, 1993
- Serum CA 125 Level Allows Early Identification of Nonresponders during Induction ChemotherapyGynecologic Oncology, 1993
- Evaluation of serum CA 125 levels in the monitoring of ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1987
- Reporting results of cancer treatmentCancer, 1981